Product Data Sheet EUMULGIN® B 1 PH General characterisation Chemical description Cetyl stearyl alcohol with 12 mol EO Labeling information INCI name(s) Ceteareth-12 Composition hints for finished product label Ceteareth-12 Registrations
Ingredient CASR-No. EINECS/ELINCS-No.
Officially listed in / Quality conforms to Ph. Eur.:
Conforms to the current analytical specification in the monograph
"Macrogoli aether cetostearylicus (Macrogol cetostearyl ether)"
Conforms to the current analytical specification in the monograph
"Macrogol cetostearyl ether" (copy of the Ph. Eur. Monograph)
Conforms to current ICH Guideline (CPMP/ICH/283/95).
encephalopathy agents Product properties Appearance EUMULGIN® B 1 PH is a white, wax-like mass with a mild odour delivered in pellets. Example of use The product can be universally applied as a non-ionic emulsifier for pharmaceutical O/ W emulsions. Characteristic values
The specifications stated in the paragraphs 'Quality control data' and 'Additional product descriptive data' finally and conclusively describe the properties of the Product.
Quality control data (Data which is used for quality release and is certified for each batch.) Appearance (colour)
Further certification: Pesticide residues
complies to the limits defined in Ph. Eur. 2.8.13 (table 1).
complies with criteria defined in Ph. Eur. 5.1.4 (catagory 2 -
topical applications; catagory 3A - oral applications).
conforms to German ordinance requirements regulating aflatoxine
conforms to German Federal Health Gazette 28, 216 1985 and
Methods of identification As described in the current Monograph of the Ph. Eur. Methods of analysis All test and assay methods are as described in the current Monograph of the Ph. Eur. Storage and transportation In the original sealed containers the product can be stored for at least two years, protected from moisture at below 30°C. Depending on the temperature, the pH value may decrease during storage. However, the product quality is not negatively influenced above a pH value of 4.0.
Revision-No. 3-06.2004 All products in the text marked with an ® are trademarks of the Cognis group.
Suggestions for processing and use of our products as well as possible formulation suggestions are provided noncommittally in accordance
with our knowledge and information. They do not discharge our customers from testing the products on suitability for processes and
purposes they are destined for. We are only liable for a damage caused intentionally or by gross negligence. However, we are under no
circumstances liable for consequential damage. Each processor is liable for the compliance of all legal regulations, including patent
Cognis does not guarantee the suitability of a product for a user-specific purpose.
P R O S T A T E Original Article I NTERNATIONAL Prostate Int 2013;1(1):37-41 • http://dx.doi.org/10.12954/PI.12005 Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice Kyung Kgi Park, Seung Hwan Lee1, Byung Ha Chung1, Su Jin Kim2, Cheol Kwak3, Hwan Cheol Son
DR. JERRY B. EMTAGE M.B. B.S. (HONS) F.R.C.S (C) DIPLOMAT OF THE AMERICAN BOARD OF UROLOGY “CHELFORD”, GEORGE WASHINGTON HOUSE Red Yeast Extract Reduces Major Coronary Events in Large, Randomized Clinical Trial CME/CE News Author: Michael O'Riordan June 16, 2008 — A large, randomized clinical trial with the partially purified extract of Chinese red yeast rice has shown that